Showing results (471-480 of 887) with videos related to
Sort By:
Pageof 89
BMC Medical Genetics|February 16, 2013
Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2Lena Dörhöfer, Alexander Lammert, Vera Krane, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 25, 2014
High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD studyChristiane Drechsler, Pieter Evenepoel, Marc G Vervloet, et al.Plos One|November 22, 2017
Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry diseaseMaria Köping, Wafaa Shehata-Dieler, Mario Cebulla, et al.Journal of Diabetes and Its Complications|March 1, 2023
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practiceNihar R Desai, Sankar D Navaneethan, Susanne B Nicholas, et al.Circulation|September 4, 2003
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging studyFrank Weidemann, Frank Breunig, Meinrad Beer, et al.Kidney International|February 5, 2019
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patientsFabian Hammer, Uwe Malzahn, Julian Donhauser, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 14, 2012
Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best PracticeWim Terryn, Pierre Cochat, Roseline Froissart, et al.Clinical Therapeutics|October 4, 2016
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 DiabetesTim Heise, Jens Jordan, Christoph Wanner, et al.Cardiovascular Diabetology|July 11, 2024
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trialDavid Fitchett, Bernard Zinman, Silvio E Inzucchi, et al.Journal of Diabetes and Its Complications|September 18, 2022
Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular riskChloë Verhagen, Jolien Janssen, Crista A Minderhoud, et al.Pageof 89